3M report “Following a medical technology assessment under the Medical Technologies Evaluation Programme, NICE has published guidance supporting the use of Tegaderm CHG dressings to cover and protect central venous and arterial catheter insertion sites in critical care patients.
NICE concluded that the uniquely designed Tegaderm dressing, with its integrated antimicrobial chlorhexidine gluconate (CHG) gel pad, offers better protection against catheter-related blood stream infections (CRBSIs), and is potentially more cost-effective compared to sterile semipermeable transparent (standard) dressings.
ReTweet if useful… New NICE guidance for reducing infection rates in intravascular care http://ctt.ec/OwU8r+ @ivteam #ivteam
CRBSIs can have devastating medical consequences for patients as they have the potential to cause severe ill-health and prolonged hospital stays. Tegaderm CHG dressing is proven to reduce the incidence of CRBSIs in critical care patients with intravascular catheters by 60% compared to standard dressings,1 thus helping to increase patient safety and improve patients’ quality of life.
Reducing length of stay in critical and high dependency care units and reducing the cost of diagnosis and treatment of CRBSIs bring obvious economic benefits to the NHS. It is known that catheter-related infections can prolong hospital stays by up to 20 days with attributable costs of around £9,900.2
If used as standard practice, the Tegaderm CHG dressing has the potential to save the NHS in England between £4.2 million and £10.8 million each year based on data reviewed by the NICE Advisory Committee (estimated cost saving per patient of £73 based on a baseline CRBSI rate of 1.48 per 1000 catheter days, benefiting population of 80,000 to 260,000.)3
The dressing’s integral chlorhexidine gel pad sits over the catheter insertion site giving antimicrobial protection while maintaining visibility of the site – a distinct advantage over CHG-impregnated sponge dressings. This allows the dressing to be used within existing care bundles*as a cost-effective method of minimising CRBSI rates.
Commenting on the NICE guidance, Dr Martin Arrowsmith, 3M Clinical Evidence and Reimbursement manager said: “Our Tegaderm CHG dressing was the first transparent antimicrobial dressing to be clinically proven and indicated to reduce CRBSIs. The publication of the NICE guidance is an important validation of the benefits of the dressing and the evidence that underpins its use.
“It highlights how the technology can support both the NHS patient safety agenda and its cost reduction strategy. We hope the official recommendation from NICE to consider using Tegaderm CHG dressings will help improve patient outcomes in critical care.”
The NICE guideline is based on review and analysis of the best clinical and economic evidence and includes the views of an expert advisory panel, including representatives of the National Infusion and Vascular Access Society, the Royal College of Nursing and the Infection Prevention Society.
Implementation of the guidance is the responsibility of local commissioners and providers when planning or delivering care of critically ill patients needing vascular access.”Download Guidance
About the National Institute for Health and Care Excellence (NICE)
The NICE guidance is available at http://www.nice.org.uk/guidance/mtg25 from 22 July 2015.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for driving improvement and excellence in the health and social care system. It develops guidance, standards and information on high-quality health and social care. It also advises on ways to promote healthy living and prevent ill health
At 3M we collaborate and apply science in powerful ways to improve lives daily. With £32 billion in sales, our 90,000 employees connect with and serve customers all around the world. Our Health Care business is dedicated to improving the practice, delivery and outcome of patient care and is a leading provider of solutions for medical, oral care, drug delivery and health information markets.
Learn about 3M’s creative solutions to the world’s problems at www.3M.co.uk or on Twitter @3M_UK or @3M_Medical_News
For more information about 3M™ Tegaderm™ CHC I.V. Securement Dressing visit
3M and Tegaderm are trademarks of the 3M Company.
3M Media contact: Julie Owen, 3M, Tel: 01509 613372 email: email@example.com
*Care bundles are a set of simple to implement evidence-based practices that when performed collectively and reliably, have been proven to improve patient outcomes.
1. Timsit JF, et al. Randomized Controlled Trial of Chlorhexidine Dressing and Highly Adhesive Dressing for Preventing Catheter-Related Infections in Critically Ill Adults. American Journal of Respiratory and Critical Care Medicine 2012; 186 (12):1272-1278.
2. Dr. Philippe Eggimann, head of the Intensive Care Unit of the University Hospital of Lausanne, Switzerland. Presentation at the 10th European Infection Prevention Expert Conference in October 2013.
3. The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites (2015) NICE medical technologies guidance MTG25